Acute Myeloid Leukemia Research Today is a free monthly online journal that collates and summarizes the latest research about Acute Myeloid Leukemia, including details on aml, symptoms, treatment, information.

Volume 2 (2005), Issue 9 (September)

1. Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891.
   Leukemia. [Abstract] [Full-text]
2. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.
   Leukemia. [Abstract] [Full-text]
3. The distal zinc finger domain of AML1/MDS1/EVI1 is an oligomerization domain involved in induction of hematopoietic differentiation defects in primary cells in vitro.
   Cancer Res, 65(17): 7603-11. [Abstract] [Full-text]
4. Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients.
   Ann Hematol. [Abstract] [Full-text]
5. Non-linear cancer classification using a modified radial basis function classification algorithm.
   J Biomed Sci. [Abstract] [Full-text]
6. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years.
   Blood, 106(6): 2113-9. [Abstract] [Full-text]
7. Defective killing of dendritic cells by autologous natural killer cells from acute myeloid leukemia patients.
   Blood, 106(6): 2186-8. [Abstract] [Full-text]
8. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.
   Blood, 106(6): 2162-8. [Abstract] [Full-text]
9. Cytotoxic activity of new cerium (III) complexes of bis-coumarins.
   Eur J Med Chem. [Abstract] [Full-text]
10. Partial tandem duplication of MLL gene in acute myeloid leukemia with translocation (11;17)(q23;q12-21).
    Am J Hematol, 80(1): 46-9. [Abstract] [Full-text]
11. FLT3 tyrosine kinase inhibitors.
    Int J Hematol, 82(2): 100-7. [Abstract] [Full-text]
12. Signal transduction of oncogenic Flt3.
    Int J Hematol, 82(2): 93-9. [Abstract] [Full-text]
13. XPD Lys751gln polymorphism: Etiology and outcome of childhood acute myeloid leukemia. A children's oncology group report.
    Blood. [Abstract] [Full-text]
14. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia (AML) by mutation of Asn-676 in the FLT3 tyrosine kinase domain.
    Blood. [Abstract] [Full-text]
15. Drug-conjugated monoclonal antibodies for the treatment of cancer.
    Curr Opin Pharmacol, 5(5): 543-9. [Abstract] [Full-text]
16. CREB: the unindicted cancer co-conspirator.
    Trends Cell Biol, 15(9): 457-9. [Abstract] [Full-text]
17. Gene expression profiling in acute myeloid leukemia.
    J Clin Oncol, 23(26): 6296-305. [Abstract] [Full-text]
18. Genetics of myeloid malignancies: pathogenetic and clinical implications.
    J Clin Oncol, 23(26): 6285-95. [Abstract] [Full-text]
19. Oligomerization of Evi-1 regulated by the PR domain contributes to recruitment of corepressor CtBP.
    Oncogene, 24(40): 6165-73. [Abstract] [Full-text]
20. PLZF-mediated control on VLA-4 expression in normal and leukemic myeloid cells.
    Oncogene. [Abstract] [Full-text]
21. HOXA gene cluster rearrangement in a t(7;9)(p15;q34) in a child with MDS.
    Cancer Genet Cytogenet, 162(1): 82-4. [Abstract] [Full-text]
22. p300/CBP-associated factor drives DEK into interchromatin granule clusters.
    J Biol Chem, 280(36): 31760-7. [Abstract] [Full-text]
23. Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia.
    Bone Marrow Transplant, 36(7): 649-54. [Abstract] [Full-text]
24. Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: 'what is the best recipe?'.
    Bone Marrow Transplant, 36(7): 565-74. [Abstract] [Full-text]
25. Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse.
    Clin Cancer Res, 11(18): 6536-43. [Abstract] [Full-text]
26. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival.
    Clin Cancer Res, 11(18): 6520-7. [Abstract] [Full-text]
27. NUP98 is fused to topoisomerase (DNA) IIbeta 180 kDa (TOP2B) in a patient with acute myeloid leukemia with a new t(3;11)(p24;p15).
    Clin Cancer Res, 11(18): 6489-94. [Abstract] [Full-text]
28. Stem cell transplantation as consolidation therapy for children in first-remission AML: a single-center report.
    Pediatr Hematol Oncol, 22(7): 597-608. [Abstract] [Full-text]
29. Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27(Kip 1) in acute myeloblastic leukemia cells.
    Leuk Res, 29(11): 1335-42. [Abstract] [Full-text]
30. Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma.
    J Clin Oncol, 23(27): 6699-711. [Abstract] [Full-text]
31. Cancer in infants: a review of 82 cases.
    Pediatr Hematol Oncol, 22(6): 463-81. [Abstract] [Full-text]
32. Phase II Trial of Amsacrine Plus Intermediate-Dose Ara-C (IDAC) with or without Etoposide as Salvage Therapy for Refractory or Relapsed Acute Leukemia.
    Jpn J Clin Oncol. [Abstract] [Full-text]
33. Myelodysplastic Syndrome with Complex Karyotypic Abnormality in a Patient with Waldenstrom's Macroglobulinemia after Sequential Treatment with Chlorambucil and Fludarabine.
    Jpn J Clin Oncol. [Abstract] [Full-text]
34. VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia.
    Ann Oncol, 16(10): 1667-74. [Abstract] [Full-text]
35. c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations.
    Blood, 106(7): 2452-61. [Abstract] [Full-text]
36. Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression.
    Blood, 106(7): 2527-9. [Abstract] [Full-text]
37. Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and prognosis of the patients.
    Blood. [Abstract] [Full-text]
38. Retinoid-mediated stimulation of steroid sulfatase activity in myeloid leukemic cell lines requires RARalpha and RXR and involves the phosphoinositide 3-kinase and ERK-MAP kinase pathways.
    J Cell Biochem. [Abstract] [Full-text]
39. Proteomic analysis of childhood leukemia.
    Leukemia, 19(10): 1713-8. [Abstract] [Full-text]
40. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
    Cancer, 104(7): 1442-52. [Abstract] [Full-text]
41. Common genetic variants in the interleukin-6 and chitotriosidase genes are associated with the risk for serious infection in children undergoing therapy for acute myeloid leukemia.
    Leukemia, 19(10): 1745-50. [Abstract] [Full-text]
42. Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells.
    Leukemia, 19(10): 1794-805. [Abstract] [Full-text]
43. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin.
    Leukemia, 19(10): 1760-7. [Abstract] [Full-text]
44. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups.
    Leukemia, 19(10): 1768-73. [Abstract] [Full-text]
45. Gatekeeper pathways and cellular background in the pathogenesis and therapy of AML.
    Leukemia, 19(10): 1719-28. [Abstract] [Full-text]
46. FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation.
    Bone Marrow Transplant. [Abstract] [Full-text]
47. Hypothesis: Myeloid-restricted hematopoietic stem cells with self-renewal capacity may be the transformation site in acute myeloid leukemia.
    Leuk Res. [Abstract] [Full-text]
48. Cyclin A1 expression and associations with disease characteristics in childhood acute lymphoblastic leukemia.
    Leuk Res. [Abstract] [Full-text]
49. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older.
    Biol Blood Marrow Transplant, 11(10): 764-72. [Abstract] [Full-text]
50. Nonfatal pulmonary Trichoderma viride infection in an adult patient with acute myeloid leukemia: report of one case and review of the literature.
    Diagn Microbiol Infect Dis, 53(1): 33-7. [Abstract] [Full-text]
51. Ocular complications in myelodysplastic syndromes as preleukemic disorders.
    Jpn J Ophthalmol, 49(5): 377-83. [Abstract] [Full-text]
52. The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis?
    Blood Rev. [Abstract] [Full-text]
53. Conjugation of lentivirus to paramagnetic particles via nonviral proteins allows efficient concentration and infection of primary acute myeloid leukemia cells.
    J Virol, 79(20): 13190-4. [Abstract] [Full-text]
54. Fanconi anemia: Current management.
    Hematology, 10: 108-10. [Abstract] [Full-text]
55. Nuclear inositol lipid metabolism: More than just second messenger generation?
    J Cell Biochem, 96(2): 285-92. [Abstract] [Full-text]
56. A role for cyclin A1 in mediating the autocrine expression of vascular endothelial growth factor in prostate cancer.
    Oncogene, 24(42): 6385-93. [Abstract] [Full-text]
57. Decitabine activates specific caspases downstream of p73 in myeloid leukemia.
    Ann Hematol. [Abstract] [Full-text]
58. Myeloid sarcoma involving the testis.
    Am J Clin Pathol, 124(3): 445-52. [Abstract] [Full-text]
59. Long-term persistence of host cells detected by X-chromosome gene-based assay in patients undergoing gender-mismatched hematopoietic stem cell transplantation.
    Am J Hematol, 80(2): 101-5. [Abstract] [Full-text]
60. Synchronous double malignancies of renal cell carcinoma and acute myeloid leukemia: An unreported co-existence.
    Am J Hematol, 80(2): 164. [Abstract] [Full-text]
61. Assessment of chemosensitivity by monitoring bcl-2 transcript kinetics in acute myeloid leukemias.
    Hematol Oncol. [Abstract] [Full-text]
62. Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States.
    J Clin Oncol, 23(28): 7032-42. [Abstract] [Full-text]
63. Liver transplantation after stem cell transplantation with the same living donor in a monozygotic twin with acute myeloid leukemia.
    Ann Hematol, 84(11): 755-757. [Abstract] [Full-text]

© 2004-2008 Acute Myeloid Leukemia Research Today. All Rights Reserved.